Yale Cancer Center, New Haven, Connecticut, United States
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects
with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk
University of California, San Francisco, San Francisco, California, United States
CC-90009-AML-002 is an exploratory Phase 1b open-label multi-arm trial to evaluate the safety
and efficacy of CC-90009 in combination with anti-leukemia agents in subjects with acute
myeloid leukemia (AML).
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
CC-90009-CP-001 is a Phase 1, single-center, open-label, clinical pharmacology study to
measure how much CC 90009 gets into the bloodstream, how much is eliminated in urine and
stool, and how long it takes the body to get rid of it. In addition, the safety and
tolerability of CC 90009 will be evaluated.